Ameriprise
LSTA icon

Ameriprise’s Lisata Therapeutics LSTA Stock Holding History

Ameriprise’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-978
Closed -$87K – 3719
2018
Q3 		$87K Sell
978
-208
-18% -$17.1K ﹤0.01% 3629
2018
Q2 		$115K Sell
1,186
-712
-38% -$50.2K ﹤0.01% 3556
2018
Q1 		$175K Buy
+1,898
New +$131K ﹤0.01% 3504
2017
Q3 		– Sell
-667
Closed -$51K – 3720
2017
Q2 		$51K Buy
+667
New +$47.1K ﹤0.01% 3682
2014
Q4 		– Sell
-2
Closed -$1K – 4102
2014
Q3 		$1K Hold
2
– – ﹤0.01% 5558
2014
Q2 		$1K Hold
2
– – ﹤0.01% 5355
2014
Q1 		$2K Hold
2
– – ﹤0.01% 5055
2013
Q4 		$2K Sell
2
-1
-33% -$989 ﹤0.01% 4882
2013
Q3 		$3K Hold
3
– – ﹤0.01% 5339
2013
Q2 		$2K Buy
+3
New +$2.63K ﹤0.01% 5329

Other funds holding LSTA

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
TFO
Tarbox Family Office Newport Beach, California $698M AUM 23.16% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Ameriprise's LSTA Position: Q4 2018 in Review

Ameriprise sold out of Lisata Therapeutics (LSTA) in Q4 2018, closing a stake of 978 shares — an estimated $87K sold.

Ameriprise first reported a position in LSTA in Q2 2013 and held it in 10 quarters. The position peaked at $175K in Q1 2018. 27 funds tracked by Wall St. Rank hold LSTA as of Q4 2018.

  • Ameriprise reported no remaining Lisata Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Ameriprise sold 978 Lisata Therapeutics shares in Q4 2018, an estimated $87K.
  • Ameriprise first reported a position in Lisata Therapeutics in Q2 2013 and held it in 10 quarters.
  • Ameriprise's Lisata Therapeutics position peaked at $175K in Q1 2018.
  • 27 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q4 2018.

Based on Ameriprise's 13F filing for Q4 2018, filed 14 Feb 2019.